Our sister publication, LCGC, covered a presentation from Scott Churchill, Vice President of Scientific Development for MCR Labs, in the Analytical Track of the Cannabis Science Conference Fall 2023.
In a presentation at the 2023 edition of the Cannabis Science Conference, Scott Churchill made two main recommendations for growers to head off the spread and invasiveness of pathogens.
While it is customary and necessary to test for things like mold, mildew, and E. coli in agricultural products, testing for all pathogens should be done to ensure a successful cannabis crop, according to Scott Churchill, vice president of scientific development for MCR Labs, based in Framingham, Massachusetts, USA (1).
Churchill spoke on the topics of screening and prevention in a lecture titled “Pathogens: Why, Where and How,” presented at the Cannabis Science Conference in Providence, Rhode Island, on September 21.
“A lot of pathogens can impact your plan that do not show up in a regulatory compliance test, or if they do, it’s going to be too late to get your full yield,” Churchill said in his presentation. “The only way that you can offset this to prevent this from happening to get a full crop yield is if you have a monitoring and management system that allows you, or you in combination with the laboratory, to identify them.”
A grower may not be able to assess pathogen-caused problems with their yield by sight, such as observing damping off or yellowing, or even weight, Churchill said, but those or other characteristics appearing as normal could mask a reduction in potency of the cannabis being cultivated. Worse yet, pathogen contamination can result in a change in genetics itself that might lead to the death of one or multiple strains of the plant, Churchill said.
The first line of defense is the cultivator, and Churchill went on to review the differing ways cultivators can best monitor pathogen exposure in and out of the lab, from the leaves down to the stems and roots. But moreover, he said, identification in the first place is key, because misdiagnosis as a lighting or watering problem could mean pathogens are still lying in wait in the soil, waiting to infect the next crop, whether it be cannabis or something else.
Two recommendations Churchill made for prevention were starting with what he called “clean stock” that ensures clones of unknown pathogenic content are not being introduced and running effective plants through multiple cycles of tissue culturing to strip out infections and return a specimen to its original genetics.
These concerns, he said, have become ever more magnified in the last decade as the cannabis market has become legalized and regulated for both medical and recreational use.
“When you translocate plants from different regions, that has to be done with extreme care, because if you bring a plant that’s infected to an area that doesn’t have any natural defense against it, it can run amok very quickly,” Churchill said. “You don’t want people smoking mold or being exposed to bacteria and so forth, but you also want to have a successful grow operation in a successful industry.”
Reference
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.